ID

42725

Description

Induction Dosing With Pegylated Interferon Alfa 2a and Ribavirin in Patients With Chronic Hepatitis C Genotype 1; ODM derived from: https://clinicaltrials.gov/show/NCT00192647

Link

https://clinicaltrials.gov/show/NCT00192647

Keywords

  1. 7/30/16 7/30/16 -
  2. 9/17/21 9/17/21 -
Uploaded on

September 17, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chronic Hepatitis C NCT00192647

Eligibility Chronic Hepatitis C NCT00192647

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male and female patients >18 and ≤75 years of age
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
serologic evidence of chronic hepatitis c infection (repeatedly anti-hcv positive and/or hcv-rna positive)
Description

Chronic Hepatitis C Evidence Serologic | Hepatitis C antibody positive | HCV viral load Positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0524910
UMLS CUI [1,2]
C0332120
UMLS CUI [1,3]
C0205473
UMLS CUI [2]
C0281863
UMLS CUI [3,1]
C1868902
UMLS CUI [3,2]
C1446409
hcv genotype 1
Description

Hepatitis C virus genotype

Data type

boolean

Alias
UMLS CUI [1]
C1148363
liver biopsy consistent with chc (a maximum window of 3 years is permitted between biopsy and study enrolment)
Description

Biopsy of liver Consistent with Hepatitis C, Chronic

Data type

boolean

Alias
UMLS CUI [1,1]
C0193388
UMLS CUI [1,2]
C0332290
UMLS CUI [1,3]
C0524910
compensated liver disease, child pugh score <7
Description

Compensated liver disease | Child-Pugh Classification

Data type

boolean

Alias
UMLS CUI [1]
C3839044
UMLS CUI [2]
C4050412
serum hcv-rna >600 iu/ml
Description

HCV viral load Serum

Data type

boolean

Alias
UMLS CUI [1,1]
C1868902
UMLS CUI [1,2]
C0229671
patients who are naïve to any hepatitis c therapy (i.e. have not been previously treated with an interferon or with ifn plus ribavirin)
Description

Therapy naive Hepatitis C | Interferons | Ribavirin

Data type

boolean

Alias
UMLS CUI [1,1]
C0919936
UMLS CUI [1,2]
C0019196
UMLS CUI [2]
C0021747
UMLS CUI [3]
C0035525
no clinical or radiological evidence of hepatocellular carcinoma and a serum afp <100 ng/ml within 2 months of randomisation
Description

Liver carcinoma Evidence | serum alpha-fetoprotein (AFP) measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C2239176
UMLS CUI [1,2]
C3887511
UMLS CUI [2]
C0546833
negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
Description

Childbearing Potential Urine pregnancy test negative | Childbearing Potential pregnancy blood test Negative | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430057
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0850355
UMLS CUI [2,3]
C0205160
UMLS CUI [3]
C0013230
all fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end
Description

Fertility Contraceptive methods | Ribavirin

Data type

boolean

Alias
UMLS CUI [1,1]
C0015895
UMLS CUI [1,2]
C0700589
UMLS CUI [2]
C0035525
australian/new zealand sites only:
Description

Site australian | Site New Zealand

Data type

boolean

Alias
UMLS CUI [1,1]
C0205145
UMLS CUI [1,2]
C0238711
UMLS CUI [2,1]
C0205145
UMLS CUI [2,2]
C0027978
patients are not required to have a liver biopsy
Description

Biopsy of liver Requirement

Data type

boolean

Alias
UMLS CUI [1,1]
C0193388
UMLS CUI [1,2]
C1514873
must meet section 100 (aus) or pharmac (nz) requirements for treatment with peginterferon alfa-2a and ribavirin
Description

peginterferon alfa-2a | Ribavirin

Data type

boolean

Alias
UMLS CUI [1]
C0391001
UMLS CUI [2]
C0035525
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
standard exclusion criteria for pegylated interferon and ribavirin.
Description

Exclusion Criteria Standard pegylated interferon alfa | Exclusion Criteria Standard Ribavirin

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1442989
UMLS CUI [1,3]
C0907160
UMLS CUI [2,1]
C0680251
UMLS CUI [2,2]
C1442989
UMLS CUI [2,3]
C0035525

Similar models

Eligibility Chronic Hepatitis C NCT00192647

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male and female patients >18 and ≤75 years of age
boolean
C0001779 (UMLS CUI [1])
Chronic Hepatitis C Evidence Serologic | Hepatitis C antibody positive | HCV viral load Positive
Item
serologic evidence of chronic hepatitis c infection (repeatedly anti-hcv positive and/or hcv-rna positive)
boolean
C0524910 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0205473 (UMLS CUI [1,3])
C0281863 (UMLS CUI [2])
C1868902 (UMLS CUI [3,1])
C1446409 (UMLS CUI [3,2])
Hepatitis C virus genotype
Item
hcv genotype 1
boolean
C1148363 (UMLS CUI [1])
Biopsy of liver Consistent with Hepatitis C, Chronic
Item
liver biopsy consistent with chc (a maximum window of 3 years is permitted between biopsy and study enrolment)
boolean
C0193388 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C0524910 (UMLS CUI [1,3])
Compensated liver disease | Child-Pugh Classification
Item
compensated liver disease, child pugh score <7
boolean
C3839044 (UMLS CUI [1])
C4050412 (UMLS CUI [2])
HCV viral load Serum
Item
serum hcv-rna >600 iu/ml
boolean
C1868902 (UMLS CUI [1,1])
C0229671 (UMLS CUI [1,2])
Therapy naive Hepatitis C | Interferons | Ribavirin
Item
patients who are naïve to any hepatitis c therapy (i.e. have not been previously treated with an interferon or with ifn plus ribavirin)
boolean
C0919936 (UMLS CUI [1,1])
C0019196 (UMLS CUI [1,2])
C0021747 (UMLS CUI [2])
C0035525 (UMLS CUI [3])
Liver carcinoma Evidence | serum alpha-fetoprotein (AFP) measurement
Item
no clinical or radiological evidence of hepatocellular carcinoma and a serum afp <100 ng/ml within 2 months of randomisation
boolean
C2239176 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
C0546833 (UMLS CUI [2])
Childbearing Potential Urine pregnancy test negative | Childbearing Potential pregnancy blood test Negative | Investigational New Drugs
Item
negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
boolean
C3831118 (UMLS CUI [1,1])
C0430057 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0850355 (UMLS CUI [2,2])
C0205160 (UMLS CUI [2,3])
C0013230 (UMLS CUI [3])
Fertility Contraceptive methods | Ribavirin
Item
all fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end
boolean
C0015895 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0035525 (UMLS CUI [2])
Site australian | Site New Zealand
Item
australian/new zealand sites only:
boolean
C0205145 (UMLS CUI [1,1])
C0238711 (UMLS CUI [1,2])
C0205145 (UMLS CUI [2,1])
C0027978 (UMLS CUI [2,2])
Biopsy of liver Requirement
Item
patients are not required to have a liver biopsy
boolean
C0193388 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
peginterferon alfa-2a | Ribavirin
Item
must meet section 100 (aus) or pharmac (nz) requirements for treatment with peginterferon alfa-2a and ribavirin
boolean
C0391001 (UMLS CUI [1])
C0035525 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Exclusion Criteria Standard pegylated interferon alfa | Exclusion Criteria Standard Ribavirin
Item
standard exclusion criteria for pegylated interferon and ribavirin.
boolean
C0680251 (UMLS CUI [1,1])
C1442989 (UMLS CUI [1,2])
C0907160 (UMLS CUI [1,3])
C0680251 (UMLS CUI [2,1])
C1442989 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial